Perrigo Fuels “Growth Engine” With Spending On New Product Pipeline
This article was originally published in The Tan Sheet
Executive Summary
Perrigo plans to file more than 10 abbreviated new drug applications before July this year, President and CEO Joe Papa said Feb. 5
You may also be interested in...
Reckitt Mucinex Patent Gets Reprieve As Appeals Court Rules Against Perrigo
An appeals court decision against Perrigo further delays the private labeler's plans to launch a Mucinex equivalent, leaving the Reckitt Benckiser decongestant still unchallenged by generic competition
NBTY Anticipates Nearly 25 Percent Boost From Leiner’s Business
Supplement manufacturer NBTY expects the addition of Leiner Health Products' business will increase its annual sales by more than $500 million - nearly 25 percent
NBTY Receiving Requests To Restart Leiner’s U.S. OTC Business
Vitamin and supplement manufacturer NBTY says it has received requests to restart Leiner Health Products' U.S. private-label OTC business, but deciding whether to make the move will take up to four months